Can Fite rises as pancreatic cancer drug shows results in pre-clinical study

Can Fite Biopharma

30/05/2023 17:40

** U.S.-listed shares of Israel-based drug developer Can
Fite Biopharma Ltd  CANF.K   CANF.TA  rise 7.7% to $2.41
    ** Co says a pre-clinical trial shows its drug, namodenoson,
significantly inhibits growth of pancreatic cancer
    ** In the study, advanced pancreatic carcinoma patient cells
were treated with co's namodenoson as a stand-alone treatment
and in combination with gemcitabine, chemotherapy used to treat
pancreatic cancer
    ** Co plans to initiate mid-stage trial to assess the
efficacy and safety of the drug in the treatment of patients
with pancreatic cancer who have received at least one previous
systemic therapy
    ** U.S-listed stock down ~60% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))